Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T cells for B-cell acute lymphoblastic leukemia with molecular relapse after allo-HSCT
ChiCTR-OOC-16008447Phase 2Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- May 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UCD19 CAR-T in acute lymphoblastic leukemia (ALL), sponsored by Xinqiao Hospital. Primary endpoint: One-year disease-free survival. Started May 2016; status: recruiting.
02
Drugs
UCD19 CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR-OOC-16008447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OOC-16008447.